DISCREPANCY BETWEEN PRESCRIBED AND ACTUAL APD PRESCRIPTION DELIVERY: IDENTIFICATION USING CYCLER REMOTE MANAGEMENT TECHNOLOGY

Catherine A Firanek¹, Mario Salas ¹, Mary Gellens¹, Rebecca Drummond Gatesman¹, Derek Wiebenson¹ and James A Sloand¹

¹Baxter Healthcare Corporation, Deerfield, IL

Poster number: MP557
June 5, 2017

Background

Non-adherence to >10% of the Peritoneal Dialysis (PD) prescription is associated with failure, peritonitis, technique hospitalizations and mortality.^{1,2} Historically, clinicians have been unable to proactively identify patients missing or shortening prescribed PDtreatments, precluding intervention. Automated Peritoneal Dialysis (APD) cyclers embedded with Patient Management Remote (RPM) technology can detect early treatment-related issues, allowing intervention to potentially prevent clinically significant events.

Objective

To evaluate actual APD treatment time compared with prescribed treatment time spent performing APD utilizing an APD device with embedded RPM technology (Claria APD System with Sharesource-Fig 1).

Methods

Data on 399 European APD patients during the period of December 2015 to December 2016 were analyzed. Patients with > 3 months on the Claria APD with RPM cycler capabilities were examined for weekly treatment frequency and actual versus prescribed treatment time. An assumption made was that patients perform APD therapy 7 days per week. Subjects with gaps in treatment >30 days were omitted/ excluded. Any treatments occurring in the first 14 days from the very first available treatment were considered as training time and were excluded. Months are considered in increments of 30 days. Time (days) on treatment was determined by counting the number of calendar days from the first treatment after the training period to the last available treatment for a E.g., If patient. a subject 125 completed days of treatment, they will be counted in the time on therapy categories of 30, 60, 90, and 120 days of treatment.

Fig 1: Remote Patient Monitoring Schemata





Fig 2: Number of Missed
Treatments in First Month of
Dialysis (N=399)

Fig 3: Number of Patients Who Missed Significant Treatment Time / Week by Week of Therapy (N=399)







Fig 4: Number of Patients With at Least 3 Months of Treatment Who Missed Significant <u>Dwell Time</u> by Week of Therapy (N=399)



Treatment frequency is a weekly rate for a specified period. It was calculated by counting the number of treatments in Sharesource/30 * 7.

If patient was found to have 27 treatments out of 30 days, then weekly rate was calculated as:

Weekly rate=(27/30) * 7 = 6.3.

Treatment differences were calculated as (Rx treatment time prescribed – actual treatment time performed.

Results

During the 1st month of therapy, 30% (115) of patients missed \geq four treatments (>10% of prescribed therapy); 12% (47) of pts missed \geq 9 treatments (Fig 2). In the first week of therapy, 24.3% (97) and 9.5% (38) of patients had ≥ 100 minutes and ≥ 300 minutes, respectively, less actual therapy time than prescribed (Fig 3). Similar results occurred over subsequent weeks. In combined results of weeks 1,2,4 and 6, 43% of pts missed >5%, 20.6% missed >10%, 11.9% missed >15% and 7% missed >20% of prescribed dwell time (Fig 4).

Summary/ Conclusions

Non-Adherence (>10%) to prescribed PD regimen associated with significant clinical negative outcomes. Current standard of care does not allow visibility for clinicians to determine adherence patterns to prescribed PD therapy. Sharesource remote patient platform allows management clinicians to securely view their patients' daily home dialysisrelated treatment data. Visibility adherence patterns may provide opportunities for clinicians to intervene, educate or retrain the patient in a more timely manner.

- 1. J Bernardini, M Nagy, B Piraino. Pattern of Noncompliance with Dialysis Exchanges in Peritoneal Dialysis Patients. *Am J Kidney Dis* 2000; 35: 1104-1110.
- 2. J Bernardini, B Piraino. Compliance in CAPD and CCPD Patients as Measured by Supply Inventories During Home Visits. *Am J Kidney Dis* 1998; 31: 107-107.









